Cargando…
A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate
INTRODUCTION: Local skin responses (LSRs) are the most common adverse effects of topical actinic keratosis (AK) therapy. There is currently no method available that allows objective characterization of LSRs. Here, the authors describe a new scale developed to quantitatively and objectively assess th...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4257948/ https://www.ncbi.nlm.nih.gov/pubmed/25073700 http://dx.doi.org/10.1007/s13555-014-0059-9 |
_version_ | 1782347822553628672 |
---|---|
author | Rosen, Robert Marmur, Ellen Anderson, Lawrence Welburn, Peter Katsamas, Janelle |
author_facet | Rosen, Robert Marmur, Ellen Anderson, Lawrence Welburn, Peter Katsamas, Janelle |
author_sort | Rosen, Robert |
collection | PubMed |
description | INTRODUCTION: Local skin responses (LSRs) are the most common adverse effects of topical actinic keratosis (AK) therapy. There is currently no method available that allows objective characterization of LSRs. Here, the authors describe a new scale developed to quantitatively and objectively assess the six most common LSRs resulting from topical AK therapy with ingenol mebutate. METHODS: The LSR grading scale was developed using a 0–4 numerical rating, with clinical descriptors and representative photographic images for each rating. Good inter-observer grading concordance was demonstrated in peer review during development of the tool. Data on the use of the scale are described from four phase III double-blind studies of ingenol mebutate (n = 1,005). RESULTS: LSRs peaked on days 4 (face/scalp) or 8 (trunk/extremities), with mean maximum composite LSR scores of 9.1 and 6.8, respectively, and a rapid return toward baseline by day 15 in most cases. Mean composite LSR score at day 57 was generally lower than at baseline. CONCLUSION: The LSR grading scale is an objective tool allowing practicing dermatologists to characterize and compare LSRs to existing and, potentially, future AK therapies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13555-014-0059-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4257948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-42579482014-12-10 A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate Rosen, Robert Marmur, Ellen Anderson, Lawrence Welburn, Peter Katsamas, Janelle Dermatol Ther (Heidelb) Original Research INTRODUCTION: Local skin responses (LSRs) are the most common adverse effects of topical actinic keratosis (AK) therapy. There is currently no method available that allows objective characterization of LSRs. Here, the authors describe a new scale developed to quantitatively and objectively assess the six most common LSRs resulting from topical AK therapy with ingenol mebutate. METHODS: The LSR grading scale was developed using a 0–4 numerical rating, with clinical descriptors and representative photographic images for each rating. Good inter-observer grading concordance was demonstrated in peer review during development of the tool. Data on the use of the scale are described from four phase III double-blind studies of ingenol mebutate (n = 1,005). RESULTS: LSRs peaked on days 4 (face/scalp) or 8 (trunk/extremities), with mean maximum composite LSR scores of 9.1 and 6.8, respectively, and a rapid return toward baseline by day 15 in most cases. Mean composite LSR score at day 57 was generally lower than at baseline. CONCLUSION: The LSR grading scale is an objective tool allowing practicing dermatologists to characterize and compare LSRs to existing and, potentially, future AK therapies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13555-014-0059-9) contains supplementary material, which is available to authorized users. Springer Healthcare 2014-07-30 /pmc/articles/PMC4257948/ /pubmed/25073700 http://dx.doi.org/10.1007/s13555-014-0059-9 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Research Rosen, Robert Marmur, Ellen Anderson, Lawrence Welburn, Peter Katsamas, Janelle A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate |
title | A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate |
title_full | A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate |
title_fullStr | A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate |
title_full_unstemmed | A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate |
title_short | A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate |
title_sort | new, objective, quantitative scale for measuring local skin responses following topical actinic keratosis therapy with ingenol mebutate |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4257948/ https://www.ncbi.nlm.nih.gov/pubmed/25073700 http://dx.doi.org/10.1007/s13555-014-0059-9 |
work_keys_str_mv | AT rosenrobert anewobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate AT marmurellen anewobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate AT andersonlawrence anewobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate AT welburnpeter anewobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate AT katsamasjanelle anewobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate AT rosenrobert newobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate AT marmurellen newobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate AT andersonlawrence newobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate AT welburnpeter newobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate AT katsamasjanelle newobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate |